Class III antiarrhythmics: Potassium channel blockers

37,300views

Class III antiarrhythmics: Potassium channel blockers

PGreen

PGreen

Cell-cell junctions
Marfan syndrome
Cellular structure and function
Development of the renal system
Mitosis and meiosis
Colorectal polyps and cancer: Pathology review
Endometrial hyperplasia and cancer: Clinical
Lung cancer
Metaplasia and dysplasia
Oral cancer
Testicular cancer
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Acute respiratory distress syndrome
Arterial disease
Asthma
Atrial septal defect
Bronchiectasis
Chronic bronchitis
Chronic venous insufficiency
Angina pectoris
Aortic valve disease
Coarctation of the aorta
Heart failure
Pneumonia
Tetralogy of Fallot
Shock
Mitral valve disease
Pericarditis and pericardial effusion
Pleural effusion
Dementia: Pathology review
Dementia: Pathology review
Dementia: Pathology review
Dementia: Pathology review
Dementia: Pathology review
Anxiety disorders: Clinical
Arteriovenous malformation
Bipolar and related disorders
Cauda equina syndrome
Seizures and epilepsy
Generalized anxiety disorder
Headaches: Pathology review
Huntington disease
Ischemic stroke
Major depressive disorder
Meningitis
Migraine
Multiple sclerosis
Panic disorder
Parkinson disease
Stroke: Clinical
Alzheimer disease
Diabetes mellitus: Pathology review
Adrenocorticotropic hormone
Chlamydia trachomatis
Cortisol
Cushing syndrome
Endometriosis
Glucagon
Glucocorticoids
Herpes simplex virus
HIV (AIDS)
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Hypothyroidism
Insulin
Pelvic inflammatory disease
Testosterone
Polycystic ovary syndrome
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Thyroid hormones
Anemia of chronic disease
Chronic leukemia
Coagulation disorders: Pathology review
Disseminated intravascular coagulation
Factor V Leiden
Hemophilia
Non-Hodgkin lymphoma
Hypocalcemia
Hypokalemia
Inflammation
Innate immune system
Introduction to the immune system
Iron deficiency anemia
Leukemias: Pathology review
Platelet disorders: Pathology review
Sickle cell disease (NORD)
Type IV hypersensitivity
Acute cholecystitis
Acute pancreatitis
Acute pyelonephritis
Alcohol-associated liver disease
Appendicitis
Autoimmune hepatitis
Biliary colic
Bowel obstruction
Chronic cholecystitis
Chronic pyelonephritis
Chronic pancreatitis
Cirrhosis
Congenital disorders: Clinical
Crohn disease
Gastroesophageal reflux disease (GERD)
Irritable bowel syndrome
Lower urinary tract infection
Nephrotic syndromes: Pathology review
Peptic ulcer
Renal failure: Pathology review
Ulcerative colitis
Urinary tract infections: Pathology review
Viral hepatitis
Acne vulgaris
Atopic dermatitis
Back pain: Pathology review
Bone disorders: Pathology review
Burns
Osteoarthritis
Osteoporosis
Paget disease of bone
Psoriasis
Rheumatoid arthritis
Skin cancer
Varicella zoster virus
Down syndrome (Trisomy 21)
Inheritance patterns
DNA damage and repair
DNA replication
Selective permeability of the cell membrane
Cell cycle
Free radicals and cellular injury
Autosomal trisomies: Pathology review
Breast cancer: Pathology review
Hypertension: Pathology review
Deep vein thrombosis
Emphysema
Endocarditis
Gas exchange in the lungs, blood and tissues
Peripheral artery disease
Pulmonary edema
Restrictive lung diseases
Stroke volume, ejection fraction, and cardiac output
Ventilation-perfusion ratios and V/Q mismatch
Cranial nerves
Migraine
Myasthenia gravis
Abnormal uterine bleeding: Clinical
Neisseria gonorrhoeae
Primary adrenal insufficiency
Benign prostatic hyperplasia
Hodgkin lymphoma
Introduction to the immune system
Celiac disease
Introduction to pharmacology
Drug administration and dosing regimens
Enzyme function
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug absorption and distribution
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Agonist, partial agonist and antagonist
Opioid antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid use disorder
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Anticoagulants: Direct factor inhibitors
Anticoagulants: Heparin
Anticoagulants: Warfarin
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Role of Vitamin K in coagulation
Vitamin B12 deficiency
Loop diuretics
Miscellaneous lipid-lowering medications
Potassium sparing diuretics
Adrenergic antagonists: Alpha blockers
Calcium channel blockers
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
Adrenergic antagonists: Beta blockers
Class II antiarrhythmics: Beta blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Class III antiarrhythmics: Potassium channel blockers
Class I antiarrhythmics: Sodium channel blockers
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
Positive inotropic medications
Vaccinations
Anthelmintic medications
Anti-mite and louse medications
Antimalarials
Hepatitis medications
Integrase and entry inhibitors
Antimetabolites: Sulfonamides and trimethoprim
Azoles
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Echinocandins
Herpesvirus medications
Mechanisms of antibiotic resistance
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Neuraminidase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Antihistamines for allergies
Miscellaneous antifungal medications
Androgens and antiandrogens
Aromatase inhibitors
Estrogens and antiestrogens
PDE5 inhibitors
Progestins and antiprogestins
Uterine stimulants and relaxants
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Non-corticosteroid immunosuppressants and immunotherapies
Hyperthyroidism medications
Hypoglycemics: Insulin secretagogues
Hypothyroidism medications
Insulins
Miscellaneous hypoglycemics
Mineralocorticoids and mineralocorticoid antagonists
Sympatholytics: Alpha-2 agonists
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Atypical antipsychotics
Atypical antidepressants
Typical antipsychotics
Lithium
Monoamine oxidase inhibitors
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Anti-parkinson medications
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Headaches: Clinical
Migraine medications
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Antigout medications
Folate (Vitamin B9) deficiency
Vitamin D
Fat-soluble vitamin deficiency and toxicity: Pathology review
Mumps virus
Measles virus
Rubella virus
Bordetella pertussis (Whooping cough)
Poliovirus
Pediatric infectious rashes: Clinical

Transcript

Watch video only

Antiarrhythmic medications help control arrhythmias, or abnormal heart beats.

There are five main groups of antiarrhythmic medications: class I, also known as sodium-channel blockers; class II, also called beta-blockers; class III, also known as potassium-channel blockers; class IV, also called calcium-channel blockers; and miscellaneous antiarrhythmics, or unclassified antiarrhythmics. Now, we’ll focus on class III antiarrhythmic medications.

Normally, an electrical signal starts at the sinoatrial or SA node in the right atrium, then propagates out through both atria, making them contract.

The signal gets delayed a bit as it goes through the atrioventricular or AV node, then goes through the Bundle of His to the Purkinje fibers of both ventricles, making them contract as well.

When the signal doesn’t follow this pathway, we get abnormal heartbeats called an arrhythmia, and there are two main causes - abnormal automaticity and abnormal reentry.

Abnormal automaticity is when an area of the heart, say, a part of the ventricle, begins to fire off action potentials at a rate that’s even faster than the SA node.

As a result, this area of the heart essentially flips roles with the SA node, firing so fast that the pacemaker cells in the SA node don’t get a chance to fire. At that point, the heartbeat is being driven by the ventricles.

Alternatively, there can be an abnormal reentry which often results from scar tissue in a ventricle after a heart attack.

Scar tissue doesn’t conduct electricity, so the signal just goes around and around the scar, and each cycle can cause the ventricles to contract.

Alternatively, there might be an accessory, or extra pathway between the atria and the ventricles, like the bundle of Kent in Wolff-Parkinson-White syndrome.

Here, the signal might move back up the accessory pathway, since oftentimes it’s bidirectional, meaning the signal can go from atrium to ventricle as well as from ventricle to atrium.

This creates a reentry circuit that causes extra contractions that occur in between the signals coming from the SA node.

Now let’s focus on a single action potential in a myocyte - it can be broken into five phases.

Here’s a graph of the membrane potential vs. time. In phase 4, which is the resting phase, the myocyte’s membrane slowly depolarizes. This is caused by the leakage of some ions - mainly calcium ions - through the gap junctions, which are openings between two neighboring cells, and that makes the membrane depolarize to the threshold potential, which marks the start of phase 0.

Phase 0 is the depolarization phase where voltage gated sodium channels open up when they reach the threshold potential, and they allow sodium to rush into the cell, creating an inward current. This rapid influx of sodium causes the myocyte’s membrane potential to become more positive.

After the membrane has depolarized, we enter Phase 1, initial repolarization. At this point the sodium channels close and the voltage-gated potassium channels open up, allowing positive potassium ions to leave the cell. This is called the outward current and the membrane potential starts to fall, and this creates a little notch on our graph.

Soon, there’s phase 2 or the plateau phase, which is when the voltage-gated calcium channels open up, and that allows positively charged calcium ions into the cell which counterbalances the potassium ions that are flowing out, so the membrane potential remains pretty stable.

During phase 3, or repolarization, the calcium channels close, but the potassium channels remain open, resulting in a net outward positive current. At the same time, ion pumps start to pump calcium ions back out of the cell and that causes the heart to relax.

Eventually the myocyte returns to the resting membrane potential and we start over with phase 4 again.

Now, class III antiarrhythmics bind and inhibit potassium (K+) channels, which are responsible for repolarization during phase 3 of the action potential in cardiomyocytes. These channels are also called cardiac delayed rectifier potassium channels, or IKr.

So, when they’re blocked, there’s less potassium leaving the cell, which leads to a slower rate of repolarization.

Ultimately, this results in the prolonged duration of action potentials and effective refractory periods, which is the period of time that the cell is unexcitable by new stimulus. On the ECG, this shows up as a longer Q-T interval.

So, longer repolarization prevents the fast conduction of the action potential throughout the heart, which eventually leads to a slower heart rate!

But, since class III antiarrhythmics prolong the QT interval, they can trigger a type of arrhythmia called torsade de pointes, which means “the twisting of points,” because the QRS complexes seem to twist around the isoelectric line.

Common medications in this class include amiodarone, dronedarone, sotalol, ibutilide, and dofetilide.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Therapeutic drug monitoring: antiarrhythmic drugs" British Journal of Clinical Pharmacology (1998)
  4. "Effects of amiodarone on short QT syndrome variant 3 in human ventricles: a simulation study" BioMedical Engineering OnLine (2017)
  5. "Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy" Vascular Health and Risk Management (2010)
  6. "Dronedarone for the treatment of atrial fibrillation and atrial flutter" Health Technology Assessment (2010)
  7. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)